Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 19/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 19/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387392 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL989002 | 0.99 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL9788808 | 0.90 | ADRA1D (0.81) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL15755824 | 0.89 | ADRA1D (0.82) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| Ambenoxan SCHEMBL2109415 | 0.78 | ADRA1D (0.64) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL13533406 | 0.77 | ADRA1D (0.63) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL10751769 | 0.77 | ADRA1D (0.63) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL10750267 | 0.77 | ADRA1D (0.63) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL4279935 | 0.77 | ADRA1D (0.62) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| SCHEMBL8097715 | 0.77 | ADRA1B (0.85) | ADRA1AADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034510-A1 | ADRENERGIC ANTAGONISTS FOR USE IN A METHOD FOR TREATING CEREBRAL EDEMA OR A BRAIN INJURY | UNIVERSITY OF ROCHESTER (US) | 2025-02-13 | — | — | WO | claimed |
| US-20220093960-A1 | BINDER SYSTEMS AND METHODS FOR TAPE CASTING LITHIUM GARNET ELECTROLYTES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | US | claimed |
| US-20020035998-A1 | Method for treatment of cancer and infectious disease | HELLSTRAND KRISTOFFER (SE) | 2002-03-28 | — | — | US | claimed |
| US-6305380-B1 | ADMINISTERING HISTAMINE AGONIST OR HT3 RECEPTOR ANTAGONIST TO ACTIVATE NATURAL KILLER CELLS AND TREAT VIRAL DISEASES | MAXIM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | claimed |
| WO-2001034124-A2 | USE OF 5HT-1A-SEROTONINE RECEPTOR AGONISTS FOR TREATING GENETIC OR FUNCTIONAL RHYTHM DISORDERS IN THE RESPIRATORY SYSTEM | RICHTER DIETHELM WOLFGANG (DE) | 2001-05-17 | — | — | WO | claimed |
| US-6162455-A | Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | claimed |
| EP-0652768-B1 | A pharmaceutical preparation for the synergistic activation of natural killer cells | MAXIM PHARM INC (US) | 2000-05-03 | — | — | EP | claimed |
| JP-9169607-A | — | — | None | — | — | JP | disclosed |
| US-20260132334-A1 | METHOD FOR PRODUCING A CERAMIC CONVERTER ELEMENT, CERAMIC CONVERTER ELEMENT, AND OPTOELECTRONIC COMPONENT | OSRAM OPTO SEMICONDUCTORS GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| US-20260124785-A1 | RAPID CERAMIC PROCESSING TECHNIQUES AND EQUIPMENT | QUANTUMSCAPE BATTERY INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109138-A1 | PROCESSING APPARATUSES AND METHODS OF USING | QUANTUMSCAPE BATTERY INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4711350-A2 | RAPID THERMAL PROCESSING METHODS AND APPARATUS | QuantumScape Battery, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533869-B2 | Processing apparatuses and methods of using | QUANTUMSCAPE BATTERY, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-4980365-A | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4957914-A | ANTIDEPRESSANTS, ANXIOLYTICS, HYPOTENSIVE AGENTS | SYNTEX (U.S.A.) INC. (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0299349-A2 | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0025727-B1 | INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | SANOFI S.A. (FR) | 1984-03-28 | — | — | EP | disclosed |
| US-4411881-A | Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines | NEW ENGLAND NUCLEAR CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4404217-A | DRUGS ACTIVE ON CARDIOVASCULAR SYSTEM | C. M. INDUSTRIES (FR) | 1983-09-13 | — | — | US | disclosed |
| US-4305944-A | TRANQUILIZERS, NEUROLEPTIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533869-B2 | Processing apparatuses and methods of using | TMCO1, ZYX, CTSZ | ADRA1D 4716/4885ADRA1A 4802/4885ADRA1B 4734/4885 |
| US-20260132334-A1 | METHOD FOR PRODUCING A CERAMIC CONVERTER ELEMENT, CERAMIC CONVERTER ELEMENT, AND OPTOELECTRONIC COMPONENT | WNT3, SPOP, YAP1 | ADRA1D 4849/4885ADRA1A 4813/4885ADRA1B 4853/4885 |
| US-20260124785-A1 | RAPID CERAMIC PROCESSING TECHNIQUES AND EQUIPMENT | ABL1, BCR, SETDB1 | ADRA1D 4051/4885ADRA1A 4623/4885ADRA1B 4325/4885 |
| US-20260109138-A1 | PROCESSING APPARATUSES AND METHODS OF USING | DSP, TMEM63A, DSG1 | ADRA1D 4676/4885ADRA1A 4800/4885ADRA1B 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.